Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

Next Previous
Search
Trial Profile

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Olaparib (Primary) ; Prednisolone; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PROpel
  • Sponsors AstraZeneca; AstraZeneca AB

    • Most Recent Events

    • 04 Mar 2025 Planned End Date changed from 4 Nov 2024 to 27 Apr 2026.
    • 05 Sep 2024 According to a Foundation Medicine media release, The FDA has granted approval to FoundationOne CDx and FoundationOne Liquid CDx the approval of the companion diagnostics follows the 2023 FDA approval of olaparib in combination with abiraterone and prednisone or prednisolone in patients with BRCA-mutated metastatic CRPC based on results of the phase 3 PROpel trial.
    • 30 Jul 2024 Planned End Date changed from 28 Apr 2026 to 4 Nov 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top